métodos estadísticos en el trasplante renal - Roche Trasplantes

ESTADÍSTICA EN BIOMEDICINA: UNA HERRAMIENTA PELIGROSA23. Langer RM, Kahan BD. Sirolimus does not increase the risk for postoperative thromboembolicevents among renal transplant recipients. Transplantation 2003; 76: 318-23.24. Lee ET, Go OT. Survival analysis in Public Health research. Annu Rev Public Health1997; 18: 105-34.25. Leung KM, Elshoff RM, Afifi AA. Censoring issues in survival analysis. Ann RevPublic Health 1997; 18: 83-104.26. Lin DY. Non-parametric inference for cumulative incidence functions in competingrisks studies. Stat Med 1997; 16: 901-10.27. Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, Lai CL, et al. Live-donor liver transplantationfor acute-on-chronic hepatitis B liver failure. Transplantation 2003; 76: 1174-9.28. Lobo PI, Isaacs RB, Spencer CE, Pruett TL, Sanfey HA, Sawyer RG, et al. Improvedspecificity and sensitivity when using pronase-digested lymphocytes to perform flowcytometriccrossmatch prior to renal transplantation. Transpl Int 2002; 15: 563-9.29. Loucaidou M, Mclean AG, Cairns TDH, Griffith M, Hakim N, Palmer A, et al. Fiveyearresults of kidney transplantation under tacrolimus-based regimes: the persistingsignificance of vascular rejection. Transplantation 2003; 76: 1120-2.30. Llorca J, Delgado-Rodríguez M. Competing risks analysis using Markov chains:impact of cerebro-vascular and ischaemic heart disease in cancer mortality. Int JEpidemiol 2001; 30: 99-101.31. Llorca J, Delgado-Rodríguez M. Competing risks in absence of independence.Impact of AIDS on liver function failure mortality, and lung cancer on ischemic heartdisease mortality. J Clin Epidemiol 2000; 53: 1145-9.32. Marcén R, Morales JM, Fernández-Juárez G, Andrés A, Pascual J, Rodicio JL, et al.Risk factors of ischemic heart disease after renal transplantation. Transplant Proc2002; 34: 394-5.33. Matl I, Bachleda P, Lao M, Michalsky R, Navratil P, Treska V, et al. Safety and efficacyof an alternative basiliximab (Simulect) regimen after renal transplantation:administration of a single 40-mg dose on the first postoperative day in patients receivingtriple therapy with azathioprine. Transpl Int 2003; 16: 45-52.34. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong riskfactor for cardiovascular death after renal transplantation. Transplantation 2003;75: 1291-5.35. Nelson W. Hazard plotting for incomplete failure data. J Quality Technology 1969;1: 27-52.36. Onoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartancilexetil decreases proteinuria in renal transplant patients with chronic allograftdysfunction. Transplantation 2003; 76: 1170-4.37. Otero A, Gómez-Gutiérrez M, Suárez F, Arnal F, Fernández-garcía A, AguirrezabalagaJ, et al. Liver transplantation form Maastricht category 2 non-heart-beating donors.Transplantation 2003; 76: 1068-73.38. Pepe MS, Longton G, Pettinger M, Mori M, Fisher DL, Storb R. Summarizing dataon survival, relapse, and chronic graft-versus-host disease after bone marrow trans-29